Phase i dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

C. R. Garrett, L. L. Siu, A. El-Khoueiry, J. Buter, C. M. Rocha-Lima, J. Marshall, P. Lorusso, P. Major, J. Chemidlin, O. Mokliatchouk, L. Velasquez, W. Hayes, D. Feltquate, S. Syed, S. Ford, G. Kollia, S. Galbraith, D. S.A. Nuyten

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences